Page 1, 2, 3
Figure: Cannabinoids and Cancer
Figure: Cannabinoids and Neurotransmitters
Endocannabinoids are fatty acid esters that act upon cannabinoid receptors. Terpenes include isoprenes, monoterpenes and sesquiterpenes. All are parts of cannabis in varying strains.
Alpha-Pinene, found in cedarwood, pine, rosemary oil and Boswellia serrata, is anti-inflammatory, broncho-dilating, stimulating, antimicrobial, and nootropic. It is also found in cannabis.
Camphene is found in camphor, mothballs, Zingiber officinale, Rosmarinus officinalis, and Salvia officinalis. It is analgesic, anti-inflammatory, sedative and antimicrobial.
Beta-Pinene is found in pine, polish, wood and also in parsley and nutmeg. It is analgesic, anti-inflammatory, stimulating, and nootropic.
Beta-Myrcene, found in Balsamic, fruit, geranium herb, cardamom, Piper nigrum, and Boswellia sacra, is anti-nociceptive, anti-inflammatory, sedative, euphoric, and anti-mutagenic.
Delta-3-Carene is found in pine, Piper nigrum, Thymus vulgaris, and star anise. It is anti-inflammatory, sedative and nootropic.
D-Limonene is found in citrus, mint, Vitex agnus-castus, Citrus limon, and celery. It is anti-tumor, anti-inflammatory, a cannabinoid agonist, antidepressant, stimulant, calming agent, nootropic and euphoric.
Ottersberg made a big point that limonene, lemon peel in hot water, will counteract cannabis overdose!!!!
This reviewer has confirmed the efficacy of this treatment very recently in a patient who accidently overconsumed an edible cannabis product. He was quite focused, non-communicative, not moving, and apparently holding on to his consciousness.
After sipping lemon peel in hot water, he immediately started to come back into regular consciousness and was able to walk. A peppermint oil drop, which is a stimulant and demulcent, licked from the back of his hand, was also very helpful. His nausea was helped by applying pressure to the acupuncture point Pericardium 6, four fingerbreadths above the inner wrist creases. Bringing him back into his body was helped by apply acupressure to Liver 3, at the junction of the large toe and second toe joints bilaterally.
I have seen several cases of cannabis overdose and have employed Governor Vessel 26, one-third of the distance between the nose and the upper lip in the midline, if consciousness is deteriorating. An acupuncture needle insertion is ideal, but a ball point pen stimulating the point, a hat pin, a sharp finger nail, and on one occasion an umbrella from a tropical drink helped bring a patient back from waning consciousness. Death or debility from overdose is highly unlikely, but the experience of the event may be disconcerting.
D-Limonene and its metabolites, perillic acid, dihydroperillic acid, uroterpenol and limonene 1, 2-diol, may inhibit tumor growth via inhibition of p21-dependent signaling and apoptosis resulting from induction of the transforming growth factor beta-signaling pathway. D-limonene induces apoptosis via the mitochondrial death pathway and suppression of the PL3K/Akt pathway in human colon cancer cells. Animal studies show activity of D-limonene against pancreatic, stomach, colon, skin, and liver cancers. Ottersberg presented 22 citations to support these data.
Fifteen more terpenoids were presented with therapeutic potentials similar to the above terpenoids in their effects.
In addition to terpenes, Ottersberg discussed cannabinoids. Cannabinoids, represented by Delta 9 Tetrahydrocannabinol are analgesic, anti-inflammatory, and antiemetic. Cannabidiol is anxiolytic, analgesic, antipsychotic, anti-inflammatory and antispasmodic. Cannabigerol is an appetite stimulant and neuroprotective. Delta9-Tetrahydrocannabinol decreases turnover of brain histamine. (Oishi R et al. J Pharmacol Exp Ther. 1985 Feb; 232(2):513-8.)
Ottersberg included a very large bibliography for his presentation.
Antonio Jimenez, MD, ND, CNC, Chief Medical Officer, Hope4Cancer Treatment Centers in Baja California, and Cancun, Mexico, spoke about what makes cancers difficult to treat with conventional therapies: tumor heterogeneity, genetic variability from tumor formation to metastasis, and the difficulty of targeting diverse metabolic pathways.
He utilizes therapies that target specific cancer-related molecular receptors/antigens, hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, monoclonal antibodies that deliver chemotherapy, cancer vaccines, gene therapy, and immunotherapies.
Figure: Immune Responses
If the immune system has it all figured out, why do we get cancer? Cancer cells are survivors and masters at immune evasion and may not present recognizable antigens. Pluripotent cancer stem cells display virtually no antigens on their surfaces. Inflammation triggers the expression of protective antigens on cancer cells, e.g. PD-L1, that suppress T cell activity. Tumors subvert macrophages and other immune cells to create its own toxic, self-defense system in the tumor micro-environment.
There are several types of immunotherapy drugs that target cancer cells and tumors:
- Monoclonal antibodies are engineered to target specific antigens and may be used to deliver chemotherapies to targeted cancers cells. The first, Rituximab, was approved in 1997 and targets CD20 on malignant B lymphocytes.
- Cytokines are substances released by T cells to kill cancer cells. The first cytokine IFN-a was approved for the treatment of cancer in 1986.
- Autologous cell therapy/cancer vaccines are immature antigens presenting cells extracted from the body, which are engineered to contain a cancer-specific antigen and are reintroduced as a vaccine. The first vaccine: Sipuleucel-T was approved in 2010 for prostate cancer.
- Oncolytic virotherapies uses viruses to locate, infect, and kill cancer cells. The first genetically unmodified oncolytic virotherapy, Riga virus, was approved in 2004; Amgen's T-VEC was the first engineered oncolytic virotherapy.
- Immune checkpoint inhibitors (ICIs) are antibodies engineered to bind to ligands on cancer cells or block receptors on T cells that inhibit their ability to kill cancer cells. The first approvals: Ipilimumab (Yervoy), a CELA-4 inhibitor: Nivolumab (Opdivo), a PD1 inhibitor.
- Adoptive T cell transfer: TCR and Car T cell therapies are personalized therapies based on modifying T cells from the patient. They involve amplification of T cells in the laboratory. Pre-treatment of patients with chemotherapy to kill immune system cells and the transfer of the CAR/TCR containing T cells to the patient is the treatment paradigm.
Jimenez raises concerns surrounding effectiveness and safety of the new immunotherapies. Serious adverse events are common and include autoimmune and inflammatory reactions, endocrinopathies, dermatitis, colitis, hepatitis, immune evasion and resistance. Currently, about 70% of patients cannot be prescribed immunotherapies at all. Hyperactivation of T cells cause unexpected organ damage, severe neurotoxicity, lowered blood pressure, and patient death from treatments. Cytokine storms from overactivation of T cells cause labored breathing, rapid pulse, high fevers, decreased blood flow to organs and coma. Pre-administration of chemotherapy/radiation is needed, resulting in the killing of the existing immune system to clear the path for engineered T cells. They are also poorly penetrating into solid tumors.
Immune checkpoint inhibitors (ICIs) have a similar panoply of side effects. ICI immunotherapy drugs will not benefit over 90% of patients of cancer patients.
Jimenez advocates 7 Key Principles of Cancer Therapy™. Non-toxic cancer therapies, immune modulation, oxygenation, full spectrum nutrition, restoration of the microbiome, detoxification and emotion and spiritual healing are the foundation of his therapy program. He uses Sono-Photo Dynamic Therapy, Interstitial PDT Laser Application, GcMAF, mistletoe therapy, and oncolytic virotherapy.
Figure: Sono-Photo Dynamic Therapy
Figure: GcMAF: Mechanism of Action Hypothesis
Mistletoe releases cytokine transmitters (e.g.IL-1, IL-6, TNF-a, IFN-g, GM-CSF). Immunomodulatory effects include increased amount and activity of many types of immune cells (e.g. dendritic cells, B-cells and T-cells). It causes indirect immune-mediated tumor inhibition and lowers susceptibility to infections.
Oncolytic virotherapy is classified as an immunotherapeutic agent in Latvia because of its specific ability to cause immune-mediated damage to tumor cells. In peripheral blood, cytotoxic CD38+, CD95+, and activated T cells are elevated along with apoptosis receptors. Repeated courses of oncolytic virotherapy taken by a patient are designed to encourage a sustained immune system response that in the long-term favors tumor rejection. It has been shown in clinical situations that repeated application of oncolytic virotherapy results in the gradual regression of lymph node micro metastases and subcutaneous metastasis in melanoma patients.
Also, hyperthermia (local and full body), autologous antigen receptor specific oncogenic targeted acquisition (AARSOTA), vitamin C IV therapy, nutrition therapy, ATP-1 personalized supplementation and nutrients, including vitamin D and propolis, lymphatic massages, and hormonal optimization are routine therapies in his clinics.
Beat Cancer and Win the Fight by How You Live
Leigh Erin Connealy, MD, graduated from the Chicago Medical School and received post-graduate training at the Harbor/UCLA Medical Center in Los Angeles. She founded The Center for New Medicine in Irvine, California, and wrote The Cancer Revolution, many articles, and appears on Dr. Detective, airing on KDOC, Roku, and Apple ETV. Her newsletter can be found at NewportNaturalHealth.com. She regards healing as caring for the whole person – body, soul and spirit – sharing the healing power of faith, hope and love while advancing science and medicine to put an end to cancer one person at a time.
Cancer is a multi-factorial disease. One particularity of cancer cells is their refusal to die. They escape apoptosis because of the failure of tumor suppressor genes that control cell cycle apoptosis. P53 is the guardian of the genome and mutation occurs in more than 50% of cancer.
The British Medical Journal of October 4, 2017 said that there was no clear evidence that most cancer drugs extend or improve life. Dr. Connealy states that the majority of cancer drugs approved in Europe between 2009 and 2013 entered the market without clear evidence that they improved survival or quality of life for patients.
Cancer is the number one killer of people, ages 1 to 85. In 1900, one person out of 100 developed cancer; today we have reached one person out of three. Very soon we will be one out of every two. Currently 1,647 die from cancer every day or 601,000 cases in the US alone annually. There are 14 million new cases per year with 8.2 million deaths every year. There has been no significant increase in survival rate over the past 35 years. Resistance to chemotherapeutic drugs is considered the greatest obstacle to the successful management of cancer patients.
Page 1, 2, 3